Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

Eskazan A. E., Tırıbellı M.

Leukemia research, vol.74, pp.55-56, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Letter
  • Volume: 74
  • Publication Date: 2018
  • Doi Number: 10.1016/j.leukres.2018.09.013
  • Journal Name: Leukemia research
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.55-56
  • Istanbul University-Cerrahpasa Affiliated: Yes